SCHEMBL12426262

SCHEMBL12426262

CC1CCCCN1CCCNC(=O)c1cnccc1Nc1nc(-c2cc(Cl)ccc2F)nc2c1CCC2

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 10/20 0.49
FLT1 P17948 1/20 0.49
FLT4 P35916 1/20 0.49
KDR P35968 1/20 0.49
MAPK8 P45983 1/20 0.49
MAPK9 P45984 1/20 0.49
MAPK10 P53779 1/20 0.49
LMNA P02545 3/20 0.45
TP53 P04637 2/20 0.45
MAPT P10636 1/20 0.45
CACNA1G O43497 6/20 0.43
ACVRL1 P37023 3/20 0.42
ACVR1B P36896 3/20 0.41
TGFBR2 P37173 3/20 0.41
CYP3A4 P08684 1/20 0.41
CSNK2A1 P68400 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426263 0.87 TGFBR1 (0.52) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL13649382 0.86 TGFBR1 (0.48) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL12426266 0.86 TGFBR1 (0.53) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL12426258 0.86 TGFBR1 (0.66) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL12426256 0.86 TGFBR1 (0.51) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL12426261 0.86 TGFBR1 (0.46) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL12426257 0.86 TGFBR1 (0.50) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL12426255 0.85 TGFBR1 (0.47) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL12426228 0.84 TGFBR1 (0.49) TGFBR1FLT1FLT4KDRMAPK8
SCHEMBL12426219 0.84 TGFBR1 (0.55) TGFBR1FLT1FLT4KDRMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977342-B2 HCV inhibiting bi-cyclic pyrimidines TIBOTEC-VIRCO VIROLOGY BVBA (BE) 2011-07-12 US disclosed
US-7977342-B2 HCV inhibiting bi-cyclic pyrimidines TIBOTEC-VIRCO VIROLOGY BVBA (BE) 2011-07-12 US disclosed
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-05 US disclosed
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-05 US disclosed
US-7223766-B2 Bi-cyclic pyrimidine inhibitors of TGFβ SCIOS, INC. (US) 2007-05-29 US disclosed
US-7223766-B2 Bi-cyclic pyrimidine inhibitors of TGFβ SCIOS, INC. (US) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES UMPS, NUDT1, PNP TGFBR1 3900/4885FLT1 2797/4885FLT4 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.